Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $38 to $41.

August 09, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals and raises the price target from $38 to $41.
The raised price target from $38 to $41 suggests a positive outlook on Apellis Pharmaceuticals' future performance, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see significant upside potential beyond the new target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100